Akers Biosciences (AKER) 3.50 $AKER
Akers' Management System Certified to ISO 13485 (2003)
GlobeNewswire - Mon Feb 09, 6:18AM CST
Akers Biosciences, Inc. (Nasdaq:AKER) (AIM:AKR.L), ("Akers" or the "Company"
, a medical device company focused on reducing the cost of healthcare through faster, easier diagnosis, announces that the Company's Management System has been certified by SAI Global, a leading global management systems Certification Body, to ISO 13485 (the "Certification" . The Certification is a requirement in certain countries to enable regulatory approval of medical devices.
AKER: 3.50 (+0.20)
Akers Presenting at US Investor Conference
GlobeNewswire - Thu Feb 05, 12:06PM CST
Akers Biosciences, Inc. (Nasdaq:AKER) (AIM:AKR.L), ("Akers" or the "Company" , a medical device company focused on reducing the cost of healthcare through faster, easier diagnosis, announces that its Executive Chairman, Raymond F. Akers Jr., Ph.D, will present to prospective investors next week at the 17 Annual BIO CEO & Investor Conference in New York City.
AKER: 3.50 (+0.20)
Latest Updates in Healthcare: Special Research on Agios, Akebia, Akers, Akorn, and Albany
PR Newswire - Tue Feb 03, 7:40AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Agios (NASDAQ: AGIO), Akebia (NASDAQ: AKBA), Akers (NASDAQ: AKER), Akorn (NASDAQ: AKRX), and Albany (NASDAQ: AMRI). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
AKRX: 47.28 (-0.25), AKER: 3.50 (+0.20), AKBA: 9.32 (+0.51), AGIO: 118.55 (+0.11), AMRI: 16.94 (-0.28)
European Patent Granted for Akers' Rapid Blood Separation Technology
GlobeNewswire - Mon Jan 26, 6:00AM CST
Akers Biosciences, Inc. (Nasdaq:AKER) (AIM:AKR.L), (the "Company" or "Akers" , a leading designer and manufacturer of rapid diagnostic screening and testing products, announces that the European Patent Office has issued a patent surrounding the Company's novel blood separator technology and method of separating a fluid fraction from whole blood (the "Technology" . Akers was granted U.S. patent protection for the Technology in 2011.
AKER: 3.50 (+0.20)
Akers Expands U.S. Sales Efforts With Key Leadership Additions
GlobeNewswire - Tue Jan 20, 6:00AM CST
Akers Biosciences, Inc. (Nasdaq:AKER) (AIM:AKR.L), (the "Company" , a leading designer and manufacturer of rapid diagnostic screening and testing products, announces the recruitment and deployment of a full-time, pan-U.S. sales and marketing team under the direction of the newly appointed Executive Vice President, Sales and Marketing, John C. Cheneval.
JNJ: 99.62 (+1.18), AKER: 3.50 (+0.20), NVS: 102.20 (-0.17)
Dave Gentry Interviews Akers Biosciences' Founder Dr. Ray Akers
GlobeNewswire - Mon Jan 05, 9:22AM CST
RedChip Companies, Inc. ("RedChip" , an international small-cap research, investor relations, and media company, today announced that "The RedChip Money Report: Small Stocks Big Money"
TM) television program host Dave Gentry interviewed Raymond F. Akers, Jr. PhD, Co-founder and Executive Chairman of Akers Biosciences (Nasdaq:AKER). During the interview, Dr. Akers provides insight into the Company's current value, growth prospects, and overall opportunity.
AKER: 3.50 (+0.20)
Bright Outlook and New Products on the Way Prompt Analyst Report of Akers Bioscience Issued by BrokerBank Securities
PR Newswire - Fri Jan 02, 6:00AM CST
Akers Bioscience Inc. (NASDAQ: AKER) has seen its shares reach new December highs on the sales success and news of the PIFA Heparin/PF4 Rapid Assay product line beginning distribution in Europe. The product line has been very successful in the US and is projected to generate significantly more revenue for the company in the upcoming year.
AKER: 3.50 (+0.20)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Dec 26, 12:03PM CST
IHT: 2.90 (-0.04), NES: 3.52 (+0.13), VJET: 10.40 (+0.45), AHC: 9.13 (+0.08), OSGB: 5.14 (+0.04), SYNC: 2.18 (+0.05), SYRX: 1.50 (-0.06), JOB: 0.79 (+0.01), LIVE: 3.23 (-0.22), PME: 2.42 (-0.07), ATOS: 1.67 (+0.11), BWEN: 5.48 (+0.15), KEG: 2.14 (+0.08), AKER: 3.50 (+0.20), XONE: 16.93 (-0.16), MCHX: 4.34 (-0.01), SPP: 1.36 (unch), RTGN: 4.20 (+0.08), ATEA: 1.76 (+0.01)
Akers Biosciences Signs European Distribution Agreements for PIFA Heparin PF4 Rapid Assay Products
GlobeNewswire - Thu Dec 18, 6:00AM CST
Akers Biosciences, Inc. (Nasdaq:AKER) (AIM:AKR.L), (the "Company" , a leading designer and manufacturer of rapid diagnostic screening and testing products, has entered into its first European distribution agreements since the installment of its international vice president in August 2014. The Company has entered into multi-year distribution agreements for PIFA Heparin/PF4 Rapid Assay products with Cryopep SARL, covering France, Belgium, the Netherlands and Luxembourg; and DiaLine AG, covering Switzerland and Lichtenstein.
AKER: 3.50 (+0.20)
Dave Gentry Features Top 5 Healthcare Stocks for 2015 on This Week's RedChip Money Report on Fox Business and Bloomberg
GlobeNewswire - Tue Dec 16, 2:52PM CST
RedChip Companies, Inc. ("RedChip" , an international small-cap research, investor relations, and media company, today announced that "The RedChip Money Report: Small Stocks Big Money" TM) television program will feature its top five healthcare companies for 2015 on Fox Business nationwide on Tuesday, December 16 at 10:00 p.m. Pacific (1 a.m. ET). The show will also air on Bloomberg Europe on Sunday, December 21 at 8:30 a.m. and 3:30 p.m. GMT; on Bloomberg U.K. Sunday, December 21 at 5:00 p.m. and 8:30 p.m. GMT; and on Bloomberg Asia on Sunday, December 21 at 3:30 p.m. HKT.
OPXA: 0.71 (-0.03), ATNM: 3.60 (-0.29), AKER: 3.50 (+0.20), CGIX: 7.07 (unch)
Akers Biosciences Announces $1 Million Initial Order to Supply PIFA Heparin/PF4 Products to China
GlobeNewswire - Wed Dec 10, 6:00AM CST
Akers Biosciences, Inc. (Nasdaq:AKER) (AIM:AKR.L), (the "Company" , a leading designer and manufacturer of rapid diagnostic screening and testing products, announces the receipt of an initial purchase order (the "Order" valued at US$1,000,000 from NovoTek Therapeutics Inc. ("NovoTek" to supply PIFA Heparin PF4/Rapid Assay products in Mainland China ("China" .
AKER: 3.50 (+0.20)
Update: My Discussion With RedChip And Thoughts Going Forward
Daniel Ward - at Seeking Alpha - Mon Dec 08, 8:08AM CST
XBI: 203.40 (+1.36), AKER: 3.50 (+0.20), AEZS: 0.53 (unch)
Cannabis (MMJ) Breathalyzer Could Follow Vertical Path of Alcohol Breathalyzer
ACCESSWIRE - Tue Dec 02, 8:40AM CST
Whitefish, MT / ACCESSWIRE / December 2, 2014 / The effects of alcohol on a driver are well documented, with motor skills and often decision-making skills decreasing with each drink, subsequently increasing the likelihood of a fatal accident. A field sobriety test (i.e. walking heel-to-toe, follow a pen with eyes, stand on one foot) typically does an ample job at helping police officers identify a driver under the influence of alcohol, which is then typically followed by the tried-and-true alcohol breathalyzer test to pinpoint blood alcohol concentration (BAC). Although some laws and penalties vary from state to state, there is a nationwide standard of drunk driving being defined as BAC at or above 0.08 percent. Technological advancements have made alcohol breathalyzers affordably available to businesses and consumers, like Akers Biosciences' (NASDAQ: AKER) CHUBE and BreathScan products, to estimate BAC. Another portable BAC estimator, Breathometer's eponymous device that operates by attaching it to the audio output of a smart phone, garnered an aggregate $1 million in investments from all five "sharks" in April on the popular CNBC show "Shark Tank," lending to the idea that it is a growing industry against the backdrop of stiffening laws and greater awareness. Breathometer isn't alone in the smart phone breathalyzer space, orders are being taken for FLOOME, a universal smartphone accessory for measuring BAC developed with the help of Proto Labs (NYSE: PRLB).
PRLB: 74.00 (+2.60), AKER: 3.50 (+0.20)
Horrendous Stock Performance Of RedChip Nation Healthcare And Biotech Stocks
Daniel Ward - at Seeking Alpha - Mon Dec 01, 10:29AM CST
INO: 6.80 (-0.15), AKER: 3.50 (+0.20)
RedChip Issues Research Update on Akers Biosciences
GlobeNewswire - Tue Nov 18, 7:40AM CST
RedChip Companies, Inc., today announced it has issued a research update on Akers Biosciences Inc. (Nasdaq:AKER), a leading designer and manufacturer of rapid diagnostic screening and testing products.
AKER: 3.50 (+0.20)
Akers Biosciences Net Loss of $1.12M
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 6:18AM CST
AKER: 3.50 (+0.20)
Akers Biosciences Announces Its Financial Results for Third Quarter 2014
GlobeNewswire - Thu Nov 13, 6:05AM CST
Akers Biosciences, Inc. (Nasdaq:AKER), (the "Company" or "ABI" , a leading designer and manufacturer of rapid diagnostic screening and testing products, reports its financial results for the third quarter ended September 30, 2014 and for the nine months ended September 30, 2014. The Form 10-Q containing the financial statements is available for viewing on the Company's website at www.akersbiosciences.com or www.sec.gov.
AKER: 3.50 (+0.20)
Akers Biosciences Announces Conference Call to Discuss Its Third Quarter and Nine Months Financial Results
GlobeNewswire - Mon Nov 10, 6:07AM CST
Akers Biosciences, Inc. (Nasdaq:AKER) (AIM:AKR.L), (the "Company" or "ABI" , a leading designer and manufacturer of rapid diagnostic screening and testing products, will hold a conference call on Thursday, November 13, 2014, at 10:30 a.m. Eastern Time to discuss its results for the third quarter and nine months ended September 30, 2014.
AKER: 3.50 (+0.20)
The Perils Of Value Microcap Research And The Example Of Akers Biosciences
Daniel Ward - at Seeking Alpha - Tue Nov 04, 12:22PM CST
AKER: 3.50 (+0.20)
Akers' Management System Certified to ISO 13485 (2003)
GlobeNewswire - Mon Feb 09, 6:18AM CST
Akers Biosciences, Inc. (Nasdaq:AKER) (AIM:AKR.L), ("Akers" or the "Company"
, a medical device company focused on reducing the cost of healthcare through faster, easier diagnosis, announces that the Company's Management System has been certified by SAI Global, a leading global management systems Certification Body, to ISO 13485 (the "Certification" . The Certification is a requirement in certain countries to enable regulatory approval of medical devices. AKER: 3.50 (+0.20)
Akers Presenting at US Investor Conference
GlobeNewswire - Thu Feb 05, 12:06PM CST
Akers Biosciences, Inc. (Nasdaq:AKER) (AIM:AKR.L), ("Akers" or the "Company"
, a medical device company focused on reducing the cost of healthcare through faster, easier diagnosis, announces that its Executive Chairman, Raymond F. Akers Jr., Ph.D, will present to prospective investors next week at the 17 Annual BIO CEO & Investor Conference in New York City. AKER: 3.50 (+0.20)
Latest Updates in Healthcare: Special Research on Agios, Akebia, Akers, Akorn, and Albany
PR Newswire - Tue Feb 03, 7:40AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Agios (NASDAQ: AGIO), Akebia (NASDAQ: AKBA), Akers (NASDAQ: AKER), Akorn (NASDAQ: AKRX), and Albany (NASDAQ: AMRI). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
AKRX: 47.28 (-0.25), AKER: 3.50 (+0.20), AKBA: 9.32 (+0.51), AGIO: 118.55 (+0.11), AMRI: 16.94 (-0.28)
European Patent Granted for Akers' Rapid Blood Separation Technology
GlobeNewswire - Mon Jan 26, 6:00AM CST
Akers Biosciences, Inc. (Nasdaq:AKER) (AIM:AKR.L), (the "Company" or "Akers"
, a leading designer and manufacturer of rapid diagnostic screening and testing products, announces that the European Patent Office has issued a patent surrounding the Company's novel blood separator technology and method of separating a fluid fraction from whole blood (the "Technology" . Akers was granted U.S. patent protection for the Technology in 2011. AKER: 3.50 (+0.20)
Akers Expands U.S. Sales Efforts With Key Leadership Additions
GlobeNewswire - Tue Jan 20, 6:00AM CST
Akers Biosciences, Inc. (Nasdaq:AKER) (AIM:AKR.L), (the "Company"
, a leading designer and manufacturer of rapid diagnostic screening and testing products, announces the recruitment and deployment of a full-time, pan-U.S. sales and marketing team under the direction of the newly appointed Executive Vice President, Sales and Marketing, John C. Cheneval. JNJ: 99.62 (+1.18), AKER: 3.50 (+0.20), NVS: 102.20 (-0.17)
Dave Gentry Interviews Akers Biosciences' Founder Dr. Ray Akers
GlobeNewswire - Mon Jan 05, 9:22AM CST
RedChip Companies, Inc. ("RedChip"
, an international small-cap research, investor relations, and media company, today announced that "The RedChip Money Report: Small Stocks Big Money" TM) television program host Dave Gentry interviewed Raymond F. Akers, Jr. PhD, Co-founder and Executive Chairman of Akers Biosciences (Nasdaq:AKER). During the interview, Dr. Akers provides insight into the Company's current value, growth prospects, and overall opportunity. AKER: 3.50 (+0.20)
Bright Outlook and New Products on the Way Prompt Analyst Report of Akers Bioscience Issued by BrokerBank Securities
PR Newswire - Fri Jan 02, 6:00AM CST
Akers Bioscience Inc. (NASDAQ: AKER) has seen its shares reach new December highs on the sales success and news of the PIFA Heparin/PF4 Rapid Assay product line beginning distribution in Europe. The product line has been very successful in the US and is projected to generate significantly more revenue for the company in the upcoming year.
AKER: 3.50 (+0.20)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Dec 26, 12:03PM CST
IHT: 2.90 (-0.04), NES: 3.52 (+0.13), VJET: 10.40 (+0.45), AHC: 9.13 (+0.08), OSGB: 5.14 (+0.04), SYNC: 2.18 (+0.05), SYRX: 1.50 (-0.06), JOB: 0.79 (+0.01), LIVE: 3.23 (-0.22), PME: 2.42 (-0.07), ATOS: 1.67 (+0.11), BWEN: 5.48 (+0.15), KEG: 2.14 (+0.08), AKER: 3.50 (+0.20), XONE: 16.93 (-0.16), MCHX: 4.34 (-0.01), SPP: 1.36 (unch), RTGN: 4.20 (+0.08), ATEA: 1.76 (+0.01)
Akers Biosciences Signs European Distribution Agreements for PIFA Heparin PF4 Rapid Assay Products
GlobeNewswire - Thu Dec 18, 6:00AM CST
Akers Biosciences, Inc. (Nasdaq:AKER) (AIM:AKR.L), (the "Company"
, a leading designer and manufacturer of rapid diagnostic screening and testing products, has entered into its first European distribution agreements since the installment of its international vice president in August 2014. The Company has entered into multi-year distribution agreements for PIFA Heparin/PF4 Rapid Assay products with Cryopep SARL, covering France, Belgium, the Netherlands and Luxembourg; and DiaLine AG, covering Switzerland and Lichtenstein. AKER: 3.50 (+0.20)
Dave Gentry Features Top 5 Healthcare Stocks for 2015 on This Week's RedChip Money Report on Fox Business and Bloomberg
GlobeNewswire - Tue Dec 16, 2:52PM CST
RedChip Companies, Inc. ("RedChip"
, an international small-cap research, investor relations, and media company, today announced that "The RedChip Money Report: Small Stocks Big Money" TM) television program will feature its top five healthcare companies for 2015 on Fox Business nationwide on Tuesday, December 16 at 10:00 p.m. Pacific (1 a.m. ET). The show will also air on Bloomberg Europe on Sunday, December 21 at 8:30 a.m. and 3:30 p.m. GMT; on Bloomberg U.K. Sunday, December 21 at 5:00 p.m. and 8:30 p.m. GMT; and on Bloomberg Asia on Sunday, December 21 at 3:30 p.m. HKT. OPXA: 0.71 (-0.03), ATNM: 3.60 (-0.29), AKER: 3.50 (+0.20), CGIX: 7.07 (unch)
Akers Biosciences Announces $1 Million Initial Order to Supply PIFA Heparin/PF4 Products to China
GlobeNewswire - Wed Dec 10, 6:00AM CST
Akers Biosciences, Inc. (Nasdaq:AKER) (AIM:AKR.L), (the "Company"
, a leading designer and manufacturer of rapid diagnostic screening and testing products, announces the receipt of an initial purchase order (the "Order" valued at US$1,000,000 from NovoTek Therapeutics Inc. ("NovoTek" to supply PIFA Heparin PF4/Rapid Assay products in Mainland China ("China" . AKER: 3.50 (+0.20)
Update: My Discussion With RedChip And Thoughts Going Forward
Daniel Ward - at Seeking Alpha - Mon Dec 08, 8:08AM CST
XBI: 203.40 (+1.36), AKER: 3.50 (+0.20), AEZS: 0.53 (unch)
Cannabis (MMJ) Breathalyzer Could Follow Vertical Path of Alcohol Breathalyzer
ACCESSWIRE - Tue Dec 02, 8:40AM CST
Whitefish, MT / ACCESSWIRE / December 2, 2014 / The effects of alcohol on a driver are well documented, with motor skills and often decision-making skills decreasing with each drink, subsequently increasing the likelihood of a fatal accident. A field sobriety test (i.e. walking heel-to-toe, follow a pen with eyes, stand on one foot) typically does an ample job at helping police officers identify a driver under the influence of alcohol, which is then typically followed by the tried-and-true alcohol breathalyzer test to pinpoint blood alcohol concentration (BAC). Although some laws and penalties vary from state to state, there is a nationwide standard of drunk driving being defined as BAC at or above 0.08 percent. Technological advancements have made alcohol breathalyzers affordably available to businesses and consumers, like Akers Biosciences' (NASDAQ: AKER) CHUBE and BreathScan products, to estimate BAC. Another portable BAC estimator, Breathometer's eponymous device that operates by attaching it to the audio output of a smart phone, garnered an aggregate $1 million in investments from all five "sharks" in April on the popular CNBC show "Shark Tank," lending to the idea that it is a growing industry against the backdrop of stiffening laws and greater awareness. Breathometer isn't alone in the smart phone breathalyzer space, orders are being taken for FLOOME, a universal smartphone accessory for measuring BAC developed with the help of Proto Labs (NYSE: PRLB).
PRLB: 74.00 (+2.60), AKER: 3.50 (+0.20)
Horrendous Stock Performance Of RedChip Nation Healthcare And Biotech Stocks
Daniel Ward - at Seeking Alpha - Mon Dec 01, 10:29AM CST
INO: 6.80 (-0.15), AKER: 3.50 (+0.20)
RedChip Issues Research Update on Akers Biosciences
GlobeNewswire - Tue Nov 18, 7:40AM CST
RedChip Companies, Inc., today announced it has issued a research update on Akers Biosciences Inc. (Nasdaq:AKER), a leading designer and manufacturer of rapid diagnostic screening and testing products.
AKER: 3.50 (+0.20)
Akers Biosciences Net Loss of $1.12M
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 6:18AM CST
AKER: 3.50 (+0.20)
Akers Biosciences Announces Its Financial Results for Third Quarter 2014
GlobeNewswire - Thu Nov 13, 6:05AM CST
Akers Biosciences, Inc. (Nasdaq:AKER), (the "Company" or "ABI"
, a leading designer and manufacturer of rapid diagnostic screening and testing products, reports its financial results for the third quarter ended September 30, 2014 and for the nine months ended September 30, 2014. The Form 10-Q containing the financial statements is available for viewing on the Company's website at www.akersbiosciences.com or www.sec.gov. AKER: 3.50 (+0.20)
Akers Biosciences Announces Conference Call to Discuss Its Third Quarter and Nine Months Financial Results
GlobeNewswire - Mon Nov 10, 6:07AM CST
Akers Biosciences, Inc. (Nasdaq:AKER) (AIM:AKR.L), (the "Company" or "ABI"
, a leading designer and manufacturer of rapid diagnostic screening and testing products, will hold a conference call on Thursday, November 13, 2014, at 10:30 a.m. Eastern Time to discuss its results for the third quarter and nine months ended September 30, 2014. AKER: 3.50 (+0.20)
The Perils Of Value Microcap Research And The Example Of Akers Biosciences
Daniel Ward - at Seeking Alpha - Tue Nov 04, 12:22PM CST
AKER: 3.50 (+0.20)
